In patients with T2DM, thiazolidinediones (TZDs) are the first oral hypoglycemic medications that increase skeletal muscle insulin sensitivity and decrease hepatic glucose synthesis by activating peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists [2]. The gene discussed is INS; the disease is type 2 diabetes mellitus.